摘要
目的观察胺碘酮联合丹参酮ⅡA磺酸钠治疗急性心肌梗死并发心房颤动(房颤)的效果。方法 98例急性心肌梗死并发房颤患者按照随机数字表法分为试验组和对照组,对照组静脉滴注胺碘酮150 mg·d^(-1);试验组静脉滴注胺碘酮150 mg·d^(-1)联合静脉滴注丹参酮ⅡA磺酸钠150 mg·d^(-1),2组均治疗10d。用酶联免疫吸附法检测治疗前后血清C反应蛋白(CRP)变化情况,并记录2组患者缺血事件发生情况。结果治疗前,试验组与对照组的血清CRP分别为(24.63±10.58),(24.57±11.12)mg·L^(-1)(P>0.05)。治疗后,试验组与对照组的血清CRP分别为(13.21±10.25),(21.52±13.22)mg·L^(-1)(P<0.05),试验组疗效较好。试验组患者心力衰竭、房颤复发率、病死率均低于对照组患者(P<0.05)。结论胺碘酮联合丹参酮ⅡA磺酸钠治疗心肌梗死并发房颤效果显著且较安全。
Objective To explore the effect of amiodarone combined with sodium tanshinon ⅡA silate in the treatment of patient with acute myocardial infarction( AMI) and atrial fibrillation(AF). Methods Ninety- eight patients with AMI complicated by AF were randomly divided into treatment group and control group according to the random number table method. The patients in the control group were given amiodarone treatment,intravenous drips 150 mg·m^-1,who in the treatment group were given amiodarone treatment,intravenous drips 150 mg·d^-1 and sodium tanshinon ⅡA silate 150 mg·d^-1 . Both the two groups were treated for 10 days. The changes of serum C reactive protein( CRP)were detected before and after treatment by the ELISA method. And the occurrence of ischemic events in the two groups were recorded.Results There was no difference in serum CRP between the treatment group and control group before treatment( P〉0. 05),of which the treatment group was( 13. 21 ± 10. 25) mg·L^-1 ,and it was significantly lower than( 21. 52 ± 13. 22) mg·L^-1 of the control group after treatment( P〈0. 05). The rates of heart failure,atrial fibrillation recurrence and mortality of the treatment group were lower than those of the control group( P〈0. 05). Conclusion The effect of amiodarone combined with sodium tanshinon ⅡA silate in the treatment of AMI with AF is significant,safe and effective.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2016年第9期781-782,785,共3页
The Chinese Journal of Clinical Pharmacology
基金
2013年度河南省医学科技攻关计划基金资助项目(201303118)
关键词
胺碘酮
丹参酮ⅡA磺酸钠
心肌梗死
房颤
amiodarone
sodium tanshinon ⅡA silate
myocardial infarction
atrial fibrillation